Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company cut its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 1.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 26,038 shares of the specialty pharmaceutical company’s stock after selling 516 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Supernus Pharmaceuticals were worth $812,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Dynamic Technology Lab Private Ltd purchased a new stake in Supernus Pharmaceuticals in the third quarter valued at approximately $352,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Supernus Pharmaceuticals by 14.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 712,395 shares of the specialty pharmaceutical company’s stock valued at $22,212,000 after acquiring an additional 91,354 shares during the period. Pacer Advisors Inc. raised its position in Supernus Pharmaceuticals by 29.9% in the 3rd quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock valued at $54,655,000 after purchasing an additional 403,028 shares during the last quarter. Intech Investment Management LLC boosted its stake in Supernus Pharmaceuticals by 16.2% during the 3rd quarter. Intech Investment Management LLC now owns 13,161 shares of the specialty pharmaceutical company’s stock worth $410,000 after purchasing an additional 1,838 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in Supernus Pharmaceuticals by 145.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 214,864 shares of the specialty pharmaceutical company’s stock worth $6,699,000 after purchasing an additional 127,420 shares during the last quarter.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock opened at $36.16 on Friday. The stock’s fifty day moving average is $35.22 and its two-hundred day moving average is $31.85. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $39.37. The firm has a market capitalization of $2.00 billion, a price-to-earnings ratio of 33.79 and a beta of 0.90.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.25. The firm had revenue of $175.70 million for the quarter, compared to analyst estimates of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. Supernus Pharmaceuticals’s revenue was up 14.2% compared to the same quarter last year. During the same quarter last year, the business earned ($0.29) earnings per share. As a group, sell-side analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Georges Gemayel sold 14,213 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $36.62, for a total transaction of $520,480.06. Following the sale, the director now directly owns 13,315 shares of the company’s stock, valued at approximately $487,595.30. The trade was a 51.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Frank Mottola sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.98, for a total value of $554,700.00. Following the sale, the senior vice president now owns 8,200 shares of the company’s stock, valued at approximately $303,236. This trade represents a 64.66 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 154,213 shares of company stock worth $5,660,180 in the last 90 days. 9.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on SUPN shares. Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Piper Sandler reaffirmed a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.